Samuel Martinez Mondragón

The intestinal microbiota has emerged as a fundamental regulator of human health, influencing physiological processes that extend far beyond the gastrointestinal tract. Growing scientific evidence indicates that alterations in microbial composition and functionality are associated with the development and progression of numerous systemic diseases, including metabolic disorders, cardiovascular disease, autoimmune conditions, inflammatory bowel disease, liver disease, and cancer. This review aimed to analyze current evidence regarding the biological mechanisms that connect intestinal microbiota with systemic pathology and to examine the potential clinical implications of microbiome-based interventions. A structured review of scientific literature published in major international biomedical databases was conducted, focusing on studies evaluating microbiota-host interactions, immune regulation, inflammatory pathways, metabolic homeostasis, and therapeutic applications. The findings demonstrate that immune dysregulation, increased intestinal permeability, chronic low-grade inflammation, and altered microbial metabolite production represent the principal mechanisms linking dysbiosis to systemic disease. Metabolic and inflammatory disorders showed the strongest associations with microbiota alterations, while growing evidence supports the role of the microbiome in cardiovascular disease, autoimmune conditions, liver disease, and oncological outcomes. Additionally, interventions such as probiotics, prebiotics, dietary modulation, synbiotics, postbiotics, and fecal microbiota-based therapies have demonstrated promising therapeutic potential. Evidence from Mexico, Colombia, and Ecuador highlights the importance of geographic and population-specific factors in shaping microbial diversity and disease susceptibility. Although important methodological and translational challenges remain, current knowledge supports the concept that intestinal microbiota represents a critical determinant of systemic health. Continued advances in microbiome research may contribute to the development of personalized preventive and therapeutic strategies across multiple medical specialties.

Bone fragility has traditionally been associated with osteoporosis and reduced bone mineral density; however, contemporary evidence indicates that fracture risk is influenced by a broader spectrum of metabolic, nutritional, endocrine, inflammatory, and musculoskeletal factors. The objective of this review was to analyze the metabolic determinants associated with bone fragility beyond osteoporosis and to examine their influence on fracture risk and recovery outcomes. A structured narrative review of scientific literature published in major biomedical databases was conducted, focusing on diabetes mellitus, chronic kidney disease, vitamin D deficiency, malnutrition, osteosarcopenia, endocrine dysfunction, and chronic inflammation. The findings demonstrated that these conditions contribute significantly to alterations in bone quality, remodeling capacity, muscle performance, and tissue repair, thereby increasing susceptibility to fragility fractures independently of bone mineral density measurements. Diabetes mellitus and chronic kidney disease emerged as major determinants of skeletal fragility due to their effects on collagen integrity, mineral metabolism, vascular function, and bone turnover. Nutritional deficiencies and inadequate vitamin D status were consistently associated with impaired mineralization, increased fall risk, and delayed fracture healing. Furthermore, osteosarcopenia highlighted the close biological relationship between bone and muscle health and its contribution to fracture susceptibility and functional decline. The evidence supports a multidimensional understanding of skeletal fragility that incorporates metabolic health into fracture prevention and management strategies. Expanding fracture risk assessment beyond traditional osteoporosis models may improve early identification of vulnerable individuals and facilitate more comprehensive approaches to prevention, treatment, and rehabilitation.

Cardiometabolic diseases, including obesity, type 2 diabetes mellitus, cardiovascular disease, and heart failure, represent a growing public health challenge throughout the Americas. The increasing prevalence of these conditions has generated interest in therapeutic strategies capable of simultaneously addressing multiple interconnected risk factors. This review aimed to analyze the current scientific evidence regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on heart failure and cardiometabolic risk. A structured literature review based on the Scientific Method was conducted using information obtained from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Cochrane Library, and major international clinical guidelines. Evidence from randomized controlled trials, systematic reviews, meta-analyses, and cardiovascular outcome studies was critically evaluated and synthesized. The findings demonstrated that GLP-1 receptor agonists consistently reduce major adverse cardiovascular events, promote significant body weight reduction, improve glycemic control, and contribute to favorable cardiometabolic outcomes. Recent studies also reported improvements in symptoms, functional capacity, and quality of life among patients with obesity-related heart failure with preserved ejection fraction. Additionally, emerging evidence suggests beneficial cardiorenal effects that further support their role within the cardiorenal-metabolic continuum. The clinical relevance of these findings is particularly important for countries such as Mexico, Colombia, and Ecuador, where obesity, diabetes, and cardiovascular disease continue to increase. In conclusion, GLP-1 receptor agonists represent an important advancement in contemporary cardiometabolic medicine and may contribute significantly to integrated prevention and management strategies aimed at reducing cardiovascular and metabolic disease burden across the Americas.